Gill Capital Partners
ABCL icon

Gill Capital Partners’s AbCellera Biologics ABCL Stock Holding History

Gill Capital Partners’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-100
Closed -$785 – 155
2026
Q2 		$785 Hold
100
– – ﹤0.01% 622
2026
Q1 		$349 Buy
+100
New +$360 ﹤0.01% 648

Other funds holding ABCL

TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Guardian Partners
Guardian Partners Toronto, Canada $1.13B AUM 28.37% 1-Year Est. Return
State of Michigan Retirement System
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 32.98% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $53.6B AUM 32.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $109B AUM 51.53% 1-Year Est. Return
Citizens Financial Group
Citizens Financial Group Providence, Rhode Island $8.58B AUM 20.32% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

Gill Capital Partners's ABCL Position: Q3 2026 in Review

Gill Capital Partners sold out of AbCellera Biologics (ABCL) in Q3 2026, closing a stake of 100 shares — an estimated $785 sold.

Gill Capital Partners first reported a position in ABCL in Q1 2026 and held it in 2 quarters. The position peaked at $785 in Q2 2026. 64 funds tracked by Wall St. Rank hold ABCL as of Q3 2026.

  • Gill Capital Partners reported no remaining AbCellera Biologics position as of Q3 2026 after selling out during the quarter.
  • Gill Capital Partners sold 100 AbCellera Biologics shares in Q3 2026, an estimated $785.
  • Gill Capital Partners first reported a position in AbCellera Biologics in Q1 2026 and held it in 2 quarters.
  • Gill Capital Partners's AbCellera Biologics position peaked at $785 in Q2 2026.
  • 64 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2026.

Based on Gill Capital Partners's 13F filing for Q3 2026, filed 13 Oct 2026.